VectivBio was a private biopharmaceutical company based in Basel, Switzerland. The company was created based on the spin-out of GLyPharma's original long-acting synthetic GLP-2 analog that was acquired by Therachon and later by Pfizer. The asset was being developed for short bowel syndrome with intestinal failure. In 2023, VectivBio was acquired by Ironwood Pharmaceuticals for $1.2B USD.
Short bowel syndrome
CTI LSF II
Syndicate
Director
January 8, 2020
VectivBio acquired by Ironwood Pharmaceuticals for $1.2B USD
Series A
VectivBio's GLP-2 analog had significant competitive advantages against other GLP-2 assets, and can be used in a more broad short-bowl syndrome population
